No CrossRef data available.
Article contents
Induction cytotoxic chemotherapy: The significance of apparent complete clinical regression after using the Price Hill Schedule A protocol for squamous carcinoma of the head and neck
Published online by Cambridge University Press: 29 June 2007
Abstract
A small group of 46 previously untreated patients out of about 260 in all who have received Price Hill schedule A cytotoxic chemotherapy, achieved apparent complete clinical regression (ACCR) of their disease before local treatment. Forty patients were classified T3 or T4, over half having clinically positive nodes at the start of treatment.
A determine survival rate of 70 per cent disease free at three years was obtained and 74 per cent achieved quality of all symptoms. Two patients declined local treatment and survived three years disease free after chemotherapy alone. No recurrence has occurred to date in seven patients achieving apparent complete histological regression (ACHAR) in their surgical specimens.
Although ACCR does not automatically improve prognosis it is likely that it does enhance the complete remission rate, especially for those also achieving ACHR.
Benefits to patients obtaining ACCR with this minimally toxic chemotherapy schedule and listed.
- Type
- Main Articles
- Information
- Copyright
- Copyright © JLO (1984) Limited 1988
References
Al Kourainy, K., Kish, J., Ensley, J., Tapazoglu, E., Jacobs, J., Weaver, A., Crissman, J., Cummings, G. and Al Sarraf, M. (1987) Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer. 59: 233–238.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
Decker, D. A., Drelichman, A., Jacobs, J., Hoschner, J., Kinzie, J., Loh, J., Weaver, A. and Al Sarraf, M. (1983). Adjuvant chemotherapy with high doses CDD II and 120 low infusion of five FU in Stage III and IV squamous cell cancer of the head and neck. Cancer. 51: 1353–1355.3.0.CO;2-I>CrossRefGoogle Scholar
Hill, B. T., Price, L. A. and MacRae, K. (1986) Importance of primary site in assessing chemotherapy response and seven year survival data in advanced squamous cell carcinomas of the head and neck treated with initial combination chemotherapy without cisplatin. Journal of Clinical Oncology. 4: 9: 1340–1347.CrossRefGoogle Scholar
Hill, B. T., Shaw, H. J., Dalley, V. M. and Price, L. A. (1984) Twenty four hour combination chemotherapy without cisplatin in patients with recurrent or metastatic head and neck cancer. American Journal of Clinical Oncology. 7: 335–340.CrossRefGoogle ScholarPubMed
Jacobs, J. R., Pajak, T. F., Kinzie, J., Al Sarraf, M., Davis, L., Hank, G. A., Weigensberg, I., Leifel, S. (1987) Induction chemotherapy in advanced head and neck cancer. Archives of Otolaryngology. 13: 193–199.CrossRefGoogle Scholar
Kies, M., Kraut, M., Gordon, L., Hawck, W., Krespi, Y. and Schiff, C. (1983) Improved survival and pre-treatment characteristics of complete responders to combination chemotherapy in advanced head and neck cancer. Proceedings of the American Society of Clinical Oncology. 29: 160.Google Scholar
Perry, D. J., Davis, R. K. and Weiss, R. B. (1982) Combined modal treatment with combination CXT in advanced squamous carcinoma of the head and neck. Proceedings of the American Society of Clinical Oncology. 1: 193.Google Scholar
Price, L. A. and Hill, B. T. (1987) Combination chemotherapy without cisplatin as initial treatment of advanced head and neck cancer: the significance of tumour site in predicting response and survival data at nine years. Second International Head and Neck Oncology Conference. Abstract. 8: 4.Google Scholar
Shaw, H. J., Price, L. A. and Hill, B. T. (1984) Treatment of advanced squamous cell carcinomas of the head and neck with initial combination chemotherapy prior to surgery and/or radiotherapy: five year survival data. Journal of Laryngology and Otology. 98: 75–82.CrossRefGoogle ScholarPubMed